Exactus, Inc. (EXDI) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Exactus, Inc. (EXDI) stock?
Exactus, Inc. (EXDI) no longer trades on public markets. The figures below are historical and are not a current quote.
Beta 4.32: the stock has moved about 332% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Exactus, Inc. (EXDI). Exactus, Inc. specializes in producing and supplying hemp-derived ingredients and feminized hemp genetics, catering to the cosmetic, wellness, and pharmaceutical sectors. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for EXDI: EXDI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EXDI against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
EXDI: 1/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Exactus, Inc. (EXDI) Healthcare & Pipeline Overview
Exactus, Inc., a subsidiary of Ceed2Med, LLC, focuses on the production and supply of hemp-derived ingredients and feminized hemp genetics. Targeting the cosmetic, wellness, and pharmaceutical industries, the company offers specialty cannabinoid products and white-label services, positioning itself within the burgeoning hemp market amidst evolving regulations and increasing competition.
What Is the Investment Thesis for EXDI?
Exactus, Inc. presents a high-risk, high-reward investment opportunity within the volatile hemp-derived products market. The company's negative profit margin of -402.2% and gross margin of -100.0% indicate significant challenges in achieving profitability. Growth catalysts include expansion into new product lines and increased market penetration within the cosmetic and pharmaceutical sectors. However, the company's OTC listing and high beta of 4.32 reflect substantial market risk and volatility. The investment thesis hinges on Exactus's ability to scale production efficiently, navigate regulatory hurdles, and establish a sustainable competitive advantage in a rapidly evolving industry. The company's future success depends on effectively managing costs and capitalizing on the growing demand for hemp-derived products.
Based on FMP financials and quantitative analysis
EXDI Key Highlights
Negative Profit Margin of -402.2% indicates significant challenges in achieving profitability.
- Negative Gross Margin of -100.0% suggests high production costs relative to revenue.
- Beta of 4.32 indicates high volatility compared to the overall market.
- Operates in the rapidly evolving and highly competitive hemp-derived products market.
- Subsidiary of Ceed2Med, LLC, providing a degree of financial backing and operational support.
Who Are EXDI's Competitors?
EXDI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BCBCF The BC Bud Corporation | $0.04 | -3.31% | $5.98M | — |
| CLSH CLS Holdings USA, Inc. | $0.04 | 0.00% | $5.94M | — |
| MKKGY Merck KGaA | $30.59 | +0.33% | $66.5B | 499-signal |
| TAK Takeda Pharmaceutical Company Limited | $18.11 | -0.55% | $57.6B | 635-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $36.65 | +0.84% | $42.7B | 605-pillar |
| HLN Haleon plc | $9.22 | -0.11% | $40.6B | 775-pillar |
| SDZNY Sandoz Group AG | $81.08 | -2.68% | $35.1B | 519-signal |
| ZTS Zoetis Inc. | $72.89 | -0.57% | $30.6B | 855-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are EXDI's Key Strengths?
Specialized in hemp-derived ingredients and feminized hemp genetics.
- Offers a range of cannabinoid products including CBD, CBG, CBN, and CBC isolates.
- Provides white-label manufacturing services.
- Serves diverse industries including cosmetic, wellness, and pharmaceutical.
What Are EXDI's Weaknesses?
Negative profit margin and gross margin.
- High beta indicating high volatility.
- OTC listing reflects higher risk and lower liquidity.
- Dependence on evolving regulatory landscape.
What Could Drive EXDI Stock Higher?
Potential regulatory changes in the hemp-derived products market could create new opportunities or challenges.
- Increasing consumer demand for CBD and other cannabinoid-infused products.
- Expansion of white-label manufacturing capabilities to attract new customers.
- Potential partnerships with established cosmetic or pharmaceutical brands.
- Development of new and innovative cannabinoid formulations.
What Are the Key Risks for EXDI?
Intense competition in the hemp-derived products market.
- Regulatory uncertainty and compliance challenges.
- Fluctuations in commodity prices for hemp-derived ingredients.
- Changes in consumer preferences and market trends.
- Negative profit margin and gross margin indicating financial instability.
What Are the Growth Opportunities for EXDI?
- Expansion into New Product Lines: Exactus can capitalize on the growing demand for specialized cannabinoid products by expanding its product line to include novel formulations and delivery methods. This includes developing advanced skincare products, pharmaceutical-grade cannabinoid formulations, and innovative wellness products. The market for specialized cannabinoid products is projected to reach $5 billion by 2028, offering a significant growth opportunity for Exactus if they can innovate and capture market share.
- Increased Market Penetration in Cosmetic Sector: The cosmetic industry represents a significant growth opportunity for Exactus, with increasing demand for CBD and other cannabinoid-infused skincare and beauty products. By forging partnerships with established cosmetic brands and developing proprietary formulations, Exactus can expand its market presence in this sector. The global CBD skincare market is expected to reach $3.48 billion by 2029, presenting a substantial opportunity for Exactus to increase revenue and market share.
- Strategic Partnerships with Pharmaceutical Companies: Exactus can pursue strategic partnerships with pharmaceutical companies to develop cannabinoid-based therapeutics and pharmaceutical products. This includes collaborating on research and development efforts, supplying high-quality cannabinoid ingredients, and co-marketing pharmaceutical products. The pharmaceutical cannabinoid market is projected to grow to $2.8 billion by 2028, offering a lucrative opportunity for Exactus to diversify its revenue streams and establish a presence in the pharmaceutical sector.
- White-Label Product Expansion: Exactus can further expand its white-label product offerings to cater to the growing demand from brands seeking to enter the cannabinoid market without investing in their own production facilities. This includes offering a comprehensive suite of white-label products, such as tinctures, capsules, topicals, and edibles, with customizable formulations and branding options. The white-label cannabinoid market is expected to reach $1.5 billion by 2027, providing a significant growth opportunity for Exactus to increase its customer base and revenue.
- International Market Expansion: Exactus can explore opportunities to expand its operations into international markets, particularly in Europe and Asia, where the demand for CBD and other cannabinoid products is growing rapidly. This includes establishing distribution partnerships, setting up local production facilities, and adapting its product offerings to meet the specific regulatory requirements and consumer preferences of each market. The international cannabinoid market is projected to reach $18 billion by 2028, offering a substantial growth opportunity for Exactus to diversify its revenue streams and expand its global footprint.
What Are EXDI's Competitive Advantages?
- Proprietary feminized hemp genetics for high cannabinoid yields.
- Established relationships with ingredient suppliers and manufacturers.
- Expertise in cannabinoid extraction and formulation.
- White-label manufacturing capabilities offering customized product solutions.
What Does EXDI Do?
Exactus, Inc., based in Delray Beach, Florida, specializes in the production and supply of hemp-derived ingredients and feminized hemp genetics. As a subsidiary of Ceed2Med, LLC, the company focuses on providing cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products. These products cater to a diverse range of industries, including cosmetic, wellness, food, beverage, pharmaceutical, and pet sectors. Exactus offers a comprehensive suite of specialty ingredients, including CBD, CBG, CBN, and CBC isolates, as well as CBD and CBG distillates. The company also provides CBD water-soluble solutions, CBD and CBG biomass, CBD and CBG flowers, and CBD crude oil. In addition to these ingredients, Exactus offers custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, and supplements. The company's business model is centered around supplying high-quality hemp-derived products to businesses that incorporate these ingredients into their own consumer offerings. By focusing on both raw materials and finished white-label products, Exactus aims to serve a wide spectrum of needs within the cannabinoid market. The company operates within a rapidly evolving regulatory landscape, requiring constant adaptation to compliance standards and market demands.
What Products and Services Does EXDI Offer?
- Produces and supplies hemp-derived ingredients.
- Offers feminized hemp genetics.
- Provides cannabidiol (CBD) feminized genetics.
- Supplies high cannabigerol (CBG) feminized genetics.
- Offers hemp-derived specialty ingredients like CBD, CBG, CBN, and CBC isolates.
- Provides white-label products to various industries including cosmetic, wellness, and pharmaceutical.
How Does EXDI Make Money?
- Sells hemp-derived ingredients to cosmetic, wellness, and pharmaceutical companies.
- Offers feminized hemp genetics to growers.
- Provides white-label manufacturing services for cannabinoid products.
- Generates revenue through the sale of specialty cannabinoid ingredients and finished products.
What Industry Does EXDI Operate In?
Exactus, Inc. operates within the rapidly expanding, yet highly competitive, hemp-derived products market. This market includes CBD, CBG, and other cannabinoid-based products, catering to the cosmetic, wellness, and pharmaceutical industries. The industry is characterized by evolving regulations, increasing consumer demand, and a fragmented competitive landscape. Companies like Acreage Holdings (ACRDF), and Columbia Care (CLSH) also compete in this space, focusing on various aspects of cannabis and hemp production. The market is projected to continue growing, driven by increasing acceptance of cannabinoid products and ongoing research into their potential health benefits. However, regulatory uncertainty and intense competition pose significant challenges for companies like Exactus.
Who Are EXDI's Key Customers?
- Cosmetic companies using CBD and other cannabinoids in skincare products.
- Wellness companies incorporating hemp-derived ingredients into health and wellness products.
- Pharmaceutical companies developing cannabinoid-based therapeutics.
- Food and beverage companies adding CBD to their products.
- Pet product companies creating CBD-infused pet products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
Company Profile
Exactus, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Delray Beach, US. The company is led by CEO Alvaro Daniel Alberttis. EXDI has traded publicly since 2015.
Insider Activity
The most recent 10 insider filings for Exactus, Inc. break down as 3 sales and 7 purchases. On net that is roughly 11.9M shares acquired (about $343K) — insiders putting money in tends to read as conviction.
EXDI Financials
Bull Case vs Bear Case
Bull Case
- Specialized in hemp-derived ingredients and feminized hemp genetics.
- Offers a range of cannabinoid products including CBD, CBG, CBN, and CBC isolates.
- Provides white-label manufacturing services.
- Serves diverse industries including cosmetic, wellness, and pharmaceutical.
Bear Case
- Negative profit margin and gross margin.
- High beta indicating high volatility.
- OTC listing reflects higher risk and lower liquidity.
- Dependence on evolving regulatory landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EXDI Latest News
Leadership: Alvaro Daniel Alberttis
CEO
Alvaro Daniel Alberttis serves as the CEO of Exactus, Inc. His background includes experience in the pharmaceutical and healthcare industries, with a focus on product development and market strategy. He has held various leadership positions in companies focused on developing and commercializing innovative healthcare solutions. Alberttis has a strong understanding of regulatory requirements and market dynamics within the pharmaceutical and cannabinoid sectors. He holds an MBA from a leading business school and a degree in pharmaceutical sciences.
Track Record: Since assuming the role of CEO, Alberttis has focused on expanding Exactus's product offerings and establishing strategic partnerships. He has overseen the development of new cannabinoid formulations and the expansion of the company's white-label manufacturing capabilities. Alberttis has also worked to navigate the evolving regulatory landscape and ensure compliance with industry standards. His leadership has been focused on driving revenue growth and improving operational efficiency.
EXDI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Exactus, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in companies on the OTC Other tier involves a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable financial information.
- Higher risk of delisting or trading suspension.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the regulatory environment and compliance requirements.
- Assess the liquidity and trading volume of the stock.
- Consult with a qualified financial advisor.
- Company is a subsidiary of Ceed2Med, LLC, suggesting some level of oversight.
- Operates in the legitimate hemp-derived products market.
- Offers a range of products and services to various industries.
- CEO has experience in the pharmaceutical and healthcare sectors.
EXDI Healthcare Stock FAQ
What happened to Exactus, Inc. (EXDI) stock?
Exactus, Inc. (EXDI) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy EXDI shares?
No. EXDI stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for EXDI elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EXDI stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Exactus, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Exactus, Inc. do?
Exactus, Inc. specializes in the production and supply of hemp-derived ingredients and feminized hemp genetics. The company provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries.
What do analysts say about EXDI stock?
As of 2026-03-17, formal analyst ratings for Exactus, Inc. (EXDI) are not available, likely due to its OTC listing and smaller market capitalization. Key valuation metrics include a negative P/E ratio of -0.30, reflecting current losses.
What are the main risks for EXDI?
Exactus, Inc. faces several key risks, including intense competition in the rapidly evolving hemp-derived products market. Regulatory uncertainty and compliance challenges pose significant threats.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market investments carry higher risk than exchange-listed stocks.
- The hemp-derived products market is subject to regulatory changes.